Coronary disease & ACS

Outcomes After Coronary Artery Bypass Grafting (CABG) Compared With FFR-Guided Percutaneous Coronary Intervention (PCI) in Patients Presenting With Acute Coronary Syndrome

JACC Cardiovasc IntervPublished Secondary analysis of the FAME 3 randomised trial

Authors' conclusion

The risk of death, MI, or stroke at 3 years was similar after CABG compared with FFR-guided PCI in patients presenting with NSTE-ACS, but reduced by CABG in patients presenting with CCS.

Study context

Population
Patients with 3-vessel CAD, presenting with NSTE-ACS (587 [39.2%]) or chronic coronary syndrome (CCS)587 (39.2%) NSTE-ACS
Participants
1,500 patients
Comparison
CABG vs fractional flow reserve (FFR)-guided PCI, in patients with vs without NSTE-ACS
Primary endpoint
Death, MI or stroke (key secondary endpoint of FAME 3), by NSTE-ACS vs CCS presentation
Follow-up
3 years
Methodological detailsinvestigator-initiated, subgroup analysis by NSTE-ACS vs CCS presentation, Median follow-up 1,080 days (Q1-Q3: 1,080-1,080 days)
  • Investigator-initiated
  • Subgroup analysis by NSTE-ACS vs CCS presentation
  • Median follow-up 1,080 days (Q1-Q3: 1,080-1,080 days)

Primary result

As reported in the abstract

Death, MI or stroke, CABG vs PCI, by presentation
CABG vs PCIAdjusted hazard ratio (95% CI)P value
NSTE-ACS
0.98(0.60–1.60)
P = 0.94
CCS
0.58(0.38–0.90)
P = 0.02

Secondary outcomes

OutcomeNSTE-ACSCCSaHR (95% CI)P value
Death, MI or stroke, NSTE-ACS vs CCS presentation · 3 years11.8%10.0%1.20 (0.81–1.77)P = 0.37
MI, CABG vs PCI (CCS subgroup) · 3 yearsCCS0.32 (0.15–0.64)P = 0.002
  • Myocardial infarction (MI), CABG vs PCI (CCS subgroup): interaction P = 0.01

Original publication

Outcomes After CABG Compared With FFR-Guided PCI in Patients Presenting With Acute Coronary Syndrome. JACC Cardiovasc Interv. Published 14 April 2025. doi:10.1016/j.jcin.2025.01.434

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.